RE: Prostate-specific antigen screening trials and prostate cancer deaths: The androgen deprivation connection

Journal of the National Cancer Institute

Volumn 106, Issue 5, 2014, Pages

  Carlsson, Sigrid ^a,b   Roobol, Monique J ^b   Schröder, Fritz H ^c   Hugosson, Jonas ^c   Auvinen, Anssi ^d  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; PROSTATE SPECIFIC ANTIGEN;

ANDROGEN DEPRIVATION THERAPY; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER SCREENING; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; DIAGNOSTIC ACCURACY; HUMAN; LETTER; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK BENEFIT ANALYSIS; VALIDITY; WATCHFUL WAITING;

EID: 84905158869     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/dju079     Document Type: Letter

References (12)

1. Haines IE, Gabor Miklos GL. Prostate-specific antigen screening trials and prostate cancer deaths: the androgen deprivation connection. J Natl Cancer Inst. 2013;105(20):1534-1539.
2. Bill-Axelson A, Holmberg L, Garmo H, et al. Radical prostatectomy or watchful waiting in early prostate cancer. N Engl J Med. 2014;370(10):932-942.
3. Andriole GL, Crawford ED, Grubb RL 3rd, et al. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst. 2012;104(2):125-132.
4. Andriole GL, Crawford ED, Grubb RL 3rd, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009;360(13):1310- 1319.
5. Pinsky PF, Blacka A, Kramer BS, Miller A, Prorok PC, Berg C. Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. Clin Trials. 2010;7(4):303-311
6. Schröder FH, Roobol MJ. ERSPC and PLCO prostate cancer screening studies: what are the differences? Eur Urol. 2010;58(1):46-52.
7. Carlsson S, vickers AJ, Roobol M, et al. Prostate cancer screening: facts, statistics, and interpretation in response to the uS Preventive Services Task Force Review. J Clin Oncol. 2012;30(21):2581-2584.
8. Wolters T, Roobol MJ, Steyerberg EW, et al. The effect of study arm on prostate cancer treatment in the large screening trial ERSPC. Int J Cancer. 2010;126(10):2387-2393.
9. Hugosson J, Carlsson S, Aus G, et al. Mortality results from the Göteborg randomised population-based prostate-cancer screening trial. Lancet Oncol. 2010;11(8):725-732.
10. Nguyen PL, Je Y, Schutz FA, Hoffman KE, Hu JC, Parekh A, Beckman JA, Choueiri TK. Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials. JAMA. 2011; 306(21): 2359-66.
11. Iversen P, Johansson JE, Lodding P, et al. Bicalutamide 150 mg in addition to standard care for patients with early non-meta-static prostate cancer: updated results from the Scandinavian Prostate Cancer Period Group-6 Study after a median follow-up period of 7.1 years. Scand J Urol Nephrol. 2006;40(6):441-452.
12. Widmark A, Klepp O, Solberg A, et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFuO-3): an open randomised phase III trial. Lancet. 2009;373(9660):301-308.